

# Aging Aseptic and Biologic Manufacturing Sites

## Design and Renovation for Compliance

### Table of Contents

#### Introduction

<b>3 Major Areas</b> .....	<b>4</b>
----------------------------	----------

<b>Process Core</b> .....	<b>5</b>
---------------------------	----------

Gray Space and White Space.....	5
---------------------------------	---

Bag Technology for Media and Buffer Solutions.....	6
--	---

Isolation of Processes .....	6
------------------------------	---

<b>Architecture</b> .....	<b>8</b>
---------------------------	----------

Unidirectional Flow .....	8
---------------------------	---

Floors.....	10
-------------	----

Wall Finishes .....	11
---------------------	----

Ceilings.....	11
---------------	----

Cleaning the Ceiling, Walls and Floor .....	12
---	----

Additional Architectural Considerations.....	12
--	----

<b>Heating, Ventilation and Air Conditioning (HVAC)</b> .....	<b>13</b>
---	-----------

Isolation.....	13
----------------	----

Waste Handling and Material Airlock .....	13
---	----

Segregation .....	14
-------------------	----

Pressurization .....	15
----------------------	----

Air Distribution .....	17
------------------------	----

Computational Fluid Dynamics (CFD).....	18
---	----

Automation.....	20
-----------------	----

Construction.....	21
-------------------	----

<b>Consequences for Aging Facilities</b> .....	<b>24</b>
--	-----------

Warning Letters.....	24
----------------------	----

Photographic Evidence of Contamination.....	26
Additional Reading.....	26
<b>Appendices.....</b>	<b>27</b>
A. Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection (FDA guidance)	
B. EU GMP Guide Annex 1: Manufacture of Sterile Medicinal Products	
C. EU GMP Guide Annex 2: Manufacture of Biological Active Substances and Medicinal Products for Human Use	